Background
==========

The staphylococci are part of the normal cutaneous ecosystem, but they are also opportunistic and invasive pathogens that cause a variety of human infections. *Staphylococcus aureus* is the most important human pathogen in this genus accounting for a high proportion of severe infections in hospitals and outpatient medical care \[[@B1]-[@B3]\]. Although the clinical relevance of coagulase negative staphylococci (CNS) is still controversial, patients at risk of CNS infections include neonates, those with intravascular catheters, prosthetic devices, postoperative sternal wound infections and immunocompromised hosts \[[@B4]-[@B7]\]. The remarkable ability of *S. aureus* and CNS to acquire antibiotic resistance limits therapeutic options, and morbidity and mortality rates of staphylococcal infections have increased the financial burden on health care systems worldwide \[[@B8]-[@B14]\].

Although there are reports on the characterization of staphylococci in Nigeria \[[@B15]-[@B18]\], many of the studies were limited to antibiotic susceptibility profiles. Moreover, one geographical region or health care institution was investigated, and CNS were not identified to species level. Only a few studies have investigated the molecular epidemiology and diversity of this group of organisms \[[@B19]-[@B23]\], however, they were not multi-centre surveys on *S. aureus* and CNS. This work describes a multi-centre study which was conducted in order to provide clinicians and infection control practitioners with information on antibiotic resistance profiles, molecular characteristics of coagulase positive and negative staphylococci, and to alert clinicians to the emergence of new clones in health care institutions (HCIs) in Nigeria.

Methods
=======

Isolation and identification of staphylococcal isolatess
--------------------------------------------------------

The study commenced with the request for non-duplicate staphylococcal isolates obtained from clinical samples processed in the microbiology laboratories of eight health care institutions in Ile-Ife, Ogbomosho, Iwo, Lagos (two centres) and Ibadan in South-West Nigeria; Jos in North-Central Nigeria, and Maiduguri in North-East Nigeria (Figure [1](#F1){ref-type="fig"}) during the period January to April, 2010. In this study, only staphylococcal isolates were analyzed and human subjects, clinical samples or human data were not investigated. All the hospitals, except the one located in Iwo, were tertiary health care institutions, each of which were at least 500-bed facilities providing medical care to about 500,000 to one million people. Preliminary verification as staphylococci was based on culture characteristics on blood agar, catalase, coagulase and DNase tests, while identification to species level was performed at the National Health Laboratory Service (NHLS), Groote Schuur Hospital, Cape Town, South Africa using the VITEK 2 system (bioMérieux, France) with the Gram-Positive Identification Card.

![Map indicating the location of the health care institutions in Nigeria.](1471-2334-12-286-1){#F1}

Antibiotic susceptibility testing
---------------------------------

Antibiotic susceptibility for penicillin G, oxacillin, teicoplanin, vancomycin, gentamicin, tetracycline, ciprofloxacin, moxifloxacin, trimethoprim/sulfamethoxazole (cotrimoxazole), fusidic acid, erythromycin, clindamycin, rifampicin, mupirocin, linezolid and tigecycline was determined by the broth microdilution method (VITEK 2 system, AST 603 cards, bioMérieux). *S. aureus* ATCC 29213 was the control strain and the VITEK 2 minimum inhibitory concentration (MIC) results were interpreted using the Advanced Expert System of the VITEK 2. Multiresistance was defined as resistance to at least three classes of antibiotics.

DNA extraction
--------------

Before DNA extraction, 5--8 colonies from an 18--24 h old culture on boiled blood agar was pretreated with lysostaphin (Sigma) (20 μg/ml for *S. aureus*; 50μg/ml for CNS) in 20 mM Tris-Cl, 2mM EDTA at 37°C for 30 min. The cells were harvested and DNA was isolated using a DNeasy tissue kit (Qiagen, Hilden, Germany).

PCR detection of the *tuf* gene
-------------------------------

Phenotypic identification of the *S. aureus* isolates was confirmed by detection of the *tuf* gene as described previously \[[@B24]\]. The PCR products were detected by gel electrophoresis using 2% w/v agarose (Seakem, Whittaker, USA) and run in 1X TAE buffer (pH 8.3) for 1 h at 100 V. Thereafter, the gel was stained with ethidium bromide, visualized under UV light and photographed using a SynGene Bioimaging System.

PCR detection of the *dfrA* gene
--------------------------------

The presence of the *dfrA* gene encoding trimethoprim resistance was investigated using the primer pairs: dfr-AF: AAT AGA CGT AAC GTC GTA CT; dfr-AR: AAG AAT GTA TGC GGT ATA GT and subsequent detection of a 289 bp product \[[@B25]\]. The PCR conditions were as follows: Initial denaturation at 95°C for 3min, followed by 30 cycles of amplification at 95°C for 30s, annealing at 55°C for 30s, extension at 72°C for 30s and final extension at 72°C for 1min.

SCC*mec* typing
---------------

SCC*mec* typing was performed according to a previously published protocol \[[@B26]\] using the control strains *S. aureus* COL (type I), N315 (type II), ANS46 (type III), MW2 (type IV), WIS (type V) and HDE288 (type VI). For non-typeable SCC*mec* elements, the investigation of *mec* complexes and *ccr* allotypes as described by Kondo et al. \[[@B27]\] was carried out on representative methicillin-resistant *S. aureus* (MRSA) and CNS isolates based on their *spa*-MLST profile and location of the health care institutions, respectively. The profiles obtained were characterized and defined according to the current nomenclature used for MRSA \[[@B28]\].

Detection of the PVL gene
-------------------------

The presence of the PVL gene was determined by PCR using primers luk-PV-1 and luk-PV-2 \[[@B29]\].

Genotyping
----------

Typing of *S. aureus* was based on sequencing of the hypervariable region of the protein A gene (*spa*). The *spa* types were assigned using the Ridom StaphType (Ridom GmbH, Würzburg, Germany, version 1.5.21) \[[@B30]\]. Multilocus sequence typing (MLST) was carried out according to the protocols described previously \[[@B31]\] on a representative isolate for the predominant and new *spa* types. PCR products were purified and sequenced at the Central Analytical Facility at the University of Stellenbosch, South Africa. Allelic profiles and sequence types (STs) were assigned using the MLST *S. aureus* database (<http://www.mlst.net>). Isolates that were not typed by MLST were assigned STs based on the Based Upon Repeat Pattern (BURP) via the Ridom StaphType software.

Results
=======

Identification and source of the staphylococcal isolates
--------------------------------------------------------

Preliminary verification of isolates obtained from the microbiology laboratories in eight HCIs in Nigeria identified 91 staphylococcal isolates (51 *S. aureus* and 40 CNS) and the characteristics of each isolate are presented in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. The clinical *S. aureus* isolates were recovered from wounds, skin and soft tissue infections (SSI), osteomyelitis and burns (36.4%), genitourinary tract infection (GTI)/infertility (18.2%), septicaemia (15.9%), urinary tract infection (UTI) (6.8%), otitis media (6.8%), bronchitis (4.5%), and 11.4% were classified as other infections (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Six species accounted for the CNS isolates: *S. haemolyticus* (n=21), *S. sciuri* (n=9), *S. saprophyticus* (n=5), *S. warneri* (n=3), *S. epidermidis* (n=1) and *S. hominis* (n=1), which were distributed across four HCIs located in Ogbomosho, Lagos (designated as Lagos2), Jos and Maiduguri (Table [3](#T3){ref-type="table"}). Most of the *S. haemolyticus* isolates were from the centres in Lagos2, Jos and Maiduguri, and 47.6% of the isolates were obtained from septicaemia, 14.3% from wound infections, 9.5% each from GTI, UTI, ocular-related infections, and those categorised as other infections (Table [3](#T3){ref-type="table"}).

###### 

Characterization of MRSA from Nigeria by antibiotic resistance pattern, detection of genes and molecular typing

  **Isolate No**   **Location**   **Sample Or Clinical Diagnosis**   **Antibiogram**                                       ***tuf*gene**   ***mecA*gene**   ***dfrA*gene**   **SCC*mec*typing**   **PVL gene**   ***spa*type**   **MLST (ST)**   **Clonal Complex (CC)**
  ---------------- -------------- ---------------------------------- ---------------------------------------------------- --------------- ---------------- ---------------- -------------------- -------------- --------------- --------------- -------------------------
  50               Lagos1         Burns                              PEN, OXA, GEN, CIP, MOX, ERY, CLI\*, TET, COT, RIF         \+               \+               \+                III                \-            t037            ST241                 CC8
  2496^ψ^          Maiduguri      GTI                                PEN, OXA, GEN, CIP, ERY, CLI, TET, COT                     \+               \+               \-               NT/UNT              \-          t037\*\*                     
  2589             Maiduguri      GTI                                PEN, OXA, GEN, CIP, ERY, CLI, TET, COT                     \+               \+               \-                 NT                \-            t037                       
  60^ψ^            Lagos1         ASOM                               PEN, OXA, TET, COT                                         \+               \+               \-                NT/V               \-          t064\*\*           ST8                  CC8
  69^¶^            Lagos1         Nasal swab/Screening               PEN, OXA, GEN, TET, COT                                    \+               \+               \-                 NT                \-            t064                       
  T39sB            Iwo            HIV/AIDS                           PEN, OXA, TET, COT                                         \+               \+               \-                 NT                \-            t064                       
  T6530            Ile-Ife        Osteomyelitis                      PEN, OXA, GEN, CIP, TET, COT                               \+               \+               \-                 IV                \-            t064                       
  TU32             Ibadan         Wound Infection                    PEN, OXA, CIP, TET, COT                                    \+               \+               \-                 NT                \-            t064                       
  TU3^ψ^           Ibadan         Wound Infection                    PEN, OXA, CIP, TET, COT                                    \+               \+               \-                NT/V               \-            t064                       
  T5056            Ile-Ife        Bronchitis                         PEN, OXA, GEN, CIP, ERY, CLI\*, TET, COT, FUS, RIF         \+               \+               \-                III                \-            t074            ST37                 CC30
  TD17             Ile-Ife        Bronchitis                         PEN, OXA, ERY, CLI                                         \+               \+               ND                 II                \-            t007            ST39       
  TN45             Ile-Ife        Wound Infection                    PEN, OXA, TET                                              \+               \+               ND                 IV                \-            t729            ST88                 CC88
  003B             Maiduguri      Septicaemia                        PEN, OXA, TET, COT                                         \+               \+               \+                 IV                \-            t1603                      
  008              Maiduguri      Septicaemia                        PEN, OXA, COT                                              \+               \+               \+                 IV                \-            t1603                      
  T5843^ψ^         Ile-Ife        Osteomyelitis                      PEN, OXA, TET, COT                                         \+               \+               \-               NT/UNT              \+          t4690\*\*         ST152              singleton

KEY:

^ψ^: Representative MRSA for SCC*mec* typing determined by Kondo *et al*. (2007).

¶Nasal samples of health care workers (HCWs) in one of the hospitals in Lagos (designated as Lagos1).

Geographical region (Nigeria): South-West (Ile-Ife, Ibadan, Iwo and Lagos); North-East (Maiduguri); North Central (Jos).

*GTI*: Genital Tract Infection; ASOM: Acute suppurative otitis media.

Antibiotics - PEN: Penicillin; OXA: Oxacillin; GEN: Gentamicin; CIP: Ciprofloxacin; MOX: Moxifloxacin; ERY: Erythromycin; CLI: Clindamycin; TET: Tetracycline; FUS: Fusidic acid; RIF: Rifampicin; COT: Cotrimoxazole; \*: Inducible resistance (clindamycin).

*UNT:* Untypeable SCC*mec* types; NT: Non-typeable; ND: Not determined.

Isolates with *spa* type t007, t074, t729 and t1603 were assigned STs based on the Based Upon Repeat Pattern (BURP) via the Ridom StaphType software.

\*\*: MLST on representative strains.

###### 

Characterization of MSSA from Nigeria by antibiotic resistance pattern, detection of genes and molecular typing

  **Isolate No**   **Location**   **Sample Or Clinical Diagnosis**   **Antibiotype**                  ***tuf*gene**   ***dfrA*gene**   **PVL gene**   ***spa*type**   **MLST (ST)**   **Clonal Complex (CC)**
  ---------------- -------------- ---------------------------------- -------------------------------- --------------- ---------------- -------------- --------------- --------------- -------------------------
  1229             Maiduguri      GTI                                TET                              \+              ND               \-             t311            ST5             CC5
  652              Maiduguri      Not available                      PEN, COT                         \+              \-               \+             t311                            
  47               Lagos1         Leg Ulcer                          PEN, TET, CIP, MOX, COT          \+              \-               \-             t064                            CC8
  54               Lagos1         SLE                                PEN, TET, COT, CIP               \+              \-               \-             t064                            
  49^¶^            Lagos1         Nasal swab/screening               PEN, COT                         \+              \-               \-             t2331\*\*       ST8             
  10               Ogbomosho      SSI                                PEN                              \+              ND               \+             t084                            CC15
  62               Lagos1         UTI                                COT                              \+              \-               \-             t084                            
  076              Maiduguri      Not available                      PEN, TET, COT                    \+              \-               \-             t084                            
  373              Maiduguri      UTI                                COT, TET                         \+              \-               \-             t084\*\*        ST15            
  1253             Maiduguri      SSI                                PEN, TET, COT                    \+              \-               \-             t084                            
  2290             Maiduguri      SSI                                PEN, TET, COT                    \+              \-               \-             t084                            
  2696             Maiduguri      Semen (Infertility)                PEN, COT                         \+              \-               \-             t084                            
  1038             Maiduguri      SSI                                PEN, COT                         \+              \-               \+             t2216                           
  2478             Maiduguri      UTI                                PEN, TET, COT                    \+              \-               \-             t2216                           
  6B               Ogbomosho      Septicaemia                        COT                              \+              \-               \+             t318            ST30            CC30
  51^¶^            Lagos1         Nasal swab/screening               PEN, COT                         \+              \-               \-             t318                            
  1059             Maiduguri      GTI                                COT                              \+              \-               \-             t318                            
  2578             Maiduguri      GTI                                PEN, TET, COT                    \+              \-               \+             t934            ST80            CC80
  56               Lagos1         Otitis media                       PEN, COT                         \+              \-               \-             t159            ST121           CC121
  67^¶^            Lagos1         Nasal swab/screening               PEN, TET, COT                    \+              \-               \+             t2304                           
  68^¶^            Lagos1         Nasal swab/screening               PEN, TET, COT                    \+              \-               \+             t2304                           
  006              Maiduguri      Septicaemia                        PEN, TET, COT                    \+              \-               \+             t355\*\*        ST152           singleton
  0017             Maiduguri      Septicaemia                        PEN, TET, COT                    \+              \-               \+             t355                            
  1097             Maiduguri      SSI                                PEN, TET, COT                    \+              \-               \+             t355                            
  2365             Maiduguri      Semen (Infertility)                PEN, COT                         \+              \-               \+             t355                            
  259              Maiduguri      Semen (Infertility)                PEN, COT                         \+              \-               \+             t355                            
  604              Maiduguri      SSI                                PEN, TET, COT                    \+              \-               \-             t355                            
  642              Maiduguri      SSI                                PEN, TET                         \+              ND               \+             **t9008**\*\*                   
  829              Maiduguri      SSI                                PEN, TET                         \+              ND               \-             **t9008**                       
  J11              Jos            Septicaemia                        PEN, TET, COT                    \+              \-               \+             t355                            
  J13              Jos            Septicaemia                        PEN, TET, COT                    \+              \-               \+             t355                            
  61               Lagos1         SSI                                TET, COT                         \+              \-               \+             **t8987**\*\*                   
  64^¶^            Lagos1         Nasal swab/screening               PEN                              \+              ND               \-             t1510           ST508           CC45
  55               Lagos1         CSOM                               PEN                              \+              ND               \-             t8223           ND              CC45
  57               Lagos1         Haematoma                          Susceptible to all antibiotics   \+              ND               \-             t635            ND              ND
  70^¶^            Lagos1         Nasal swab/screening               PEN, TET, COT                    \+              \-               \-             NT              ND              ND

KEY:

^¶^: Nasal samples of health care workers (HCWs) in one of the hospitals in Lagos (designated as Lagos1).

*GTI:* Genital Tract Infection; SLE: systemic lupus erythematosus; SSI: Skin and soft tissue infection; UTI: Urinary Tract Infection; CSOM: Chronic suppurative otitis media.

Antibiotics - PEN: Penicillin; TET: Tetracycline; CIP: Ciprofloxacin; MOX: Moxifloxacin; COT: Cotrimoxazole.

*ND:* Not determined; NT: Non-typeable.

*Spa* types (bold) are new types; Isolates with *spa* type t064, t159, t311, t318, t934, 1510, t2216 and t2304 were assigned STs based on the Based Upon Repeat Pattern (BURP) via the Ridom StaphType software. \*\*: MLST on representative strains.

###### 

**Identification and Characterization of CNS by antibiotic resistance pattern,*mecA*gene detection and SCC*mec*typing**

  **Isolate No**   **Location**   **Sample/Clinical Condition**   **VITEK 2 Identification**                   **Antibiogram**                  ***mecA*gene**   **SCC*mec*Typing**
  ---------------- -------------- ------------------------------- ---------------------------- ----------------------------------------------- ---------------- --------------------
  2                Ogbomosho      Wound Infection                 *S. saprophyticus*                         PEN, TET, COT, FUS                       \-                 ND
  4                Ogbomosho      UTI                             *S. saprophyticus*                         PEN, TET, COT, FUS                       \-                 ND
  7                Ogbomosho      Osteomyelitis                   *S. saprophyticus*                         PEN, TET, COT, FUS                       \-                 ND
  13B              Ogbomosho      UTI                             *S. saprophyticus*                            PEN, COT, FUS                         \-                 ND
  14^ψ^            Ogbomosho      Septicaemia                     *S. sciuri*                           PEN, OXA, GEN, CIP, FUS, MOX                  \+               NT/UNT
  16               Ogbomosho      SSI                             *S. warneri*                               PEN, TET, COT, FUS                       \-                 ND
  16B              Ogbomosho      Osteomyelitis                   *S. warneri*                                  TET, COT, FUS                         \-                 ND
  18               Ogbomosho      SSI                             *S. saprophyticus*                         PEN, TET, COT, FUS                       \-                 ND
  66               Lagos2         Wound Infection                 *S. sciuri*                              PEN, OXA, GEN, CIP, FUS                    \+                 NT
  L2^ψ^            Lagos2         Septicaemia                     *S. haemolyticus*                          PEN, OXA, TET, COT                       \+                NT/V
  L5               Lagos2         Eye swab                        *S. haemolyticus*                     PEN, OXA, CIP, MOX, TET, COT                  \+                 NT
  L6               Lagos2         Septicaemia                     *S. haemolyticus*                PEN, OXA, GEN, CIP, ERY, TET, RIF, COT             \+                 NT
  L7               Lagos2         Septicaemia                     *S. haemolyticus*                PEN, OXA, GEN, CIP, MOX, ERY, TET, COT             \+                 NT
  L8               Lagos2         Septicaemia                     *S. haemolyticus*               PEN, OXA, GEN, CIP, ERY, CLI\*, TET, COT            \+                 NT
  L9               Lagos2         Septicaemia                     *S. haemolyticus*                     PEN, OXA, GEN, CIP, TET, COT                  \+                 NT
  L10              Lagos2         Eye swab                        *S. haemolyticus*                PEN, OXA, GEN, CIP, MOX, ERY, TET, COT             \+                 NT
  1103             Maiduguri      Wound Infection                 *S. warneri*                                  PEN, OXA, TET                         \+                 NT
  1268             Maiduguri      Wound Infection                 *S. haemolyticus*                   PEN, OXA, GEN, CIP, MOX, TET, COT               \+                 NT
  024^ψ^           Maiduguri      Wound Infection                 *S. haemolyticus*                        PEN, OXA, GEN, TET, COT                    \+                NT/V
  2491             Maiduguri      UTI                             *S. haemolyticus*               PEN, OXA, GEN, CIP, ERY, TET, COT, TEICOi           \+                 NT
  2412             Maiduguri      Wound Infection                 *S. haemolyticus*                   PEN, OXA, GEN, CIP, MOX, TET, COT               \+                 NT
  2362 ^ψ^         Maiduguri      GTI                             *S. haemolyticus*               PEN, OXA, GEN, CIP, ERY, CLI\*, TET, COT            \+               NT/UNT
  825              Maiduguri      GTI                             *S. haemolyticus*                     PEN, OXA, GEN, CIP, TET, COT                  \+                 NT
  2502             Maiduguri      UTI                             *S. haemolyticus*                          PEN, OXA, GEN, COT                       ND                 ND
  J2               Jos            Septicaemia                     *S. hominis*                                  PEN, OXA, TET                         ND                 ND
  J5               Jos            Septicaemia                     *S. haemolyticus*             PEN, OXA, GEN, CIP, ERY, CLI\*, TET, RIF, COT         ND                 ND
  J6               Jos            Septicaemia                     *S. haemolyticus*             PEN, OXA, GEN, CIP, ERY, CLI\*, TET, RIF, COT         ND                 ND
  J10              Jos            Septicaemia                     *S. haemolyticus*             PEN, OXA, GEN, CIP, ERY, CLI\*, TET, RIF, COT         ND                 ND
  J14^ψ^           Jos            Septicaemia                     *S. haemolyticus*                PEN, OXA, GEN, CIP, ERY, TET, FUS, COT             \+                NT/V
  J15              Jos            Prostatis                       *S. haemolyticus*                          PEN, OXA, TET, COT                       \+                 NT
  J16              Jos            Otitis media                    *S. haemolyticus*                        PEN, OXA, GEN, CIP, COT                    \+                 NT
  J17B             Jos            Osteomyelitis                   *S. epidermidis*                              PEN, OXA, COT                         \+                 NT
  151              Ogbomosho      Septicaemia                     *S. haemolyticus*                   PEN, OXA, GEN, CIP, MOX, TET, COT               \+                 NT
  12               Ogbomosho      Conjunctivitis                  *S. sciuri*                              PEN, OXA, GEN, CIP, FUS                    \+                 NT
  19B              Ogbomosho      SSI                             *S. sciuri*                           PEN, OXA, GEN, CIP, TET, FUS                  \+                 NT
  11               Ogbomosho      Wound abscess                   *S. sciuri*                              PEN, OXA, GEN, CIP, FUS                    \+                 NT
  17               Ogbomosho      Wound infection                 *S. sciuri*                              PEN, OXA, CIP, GEN, FUS                    \+                 NT
  11B              Ogbomosho      UTI                             *S. sciuri*                           PEN, OXA, GEN, CIP, MOX, FUS                  \+                 NT
  15               Ogbomosho      UTI                             *S. sciuri*                           PEN, OXA, GEN, CIP, MOX, FUS                  \+                 NT
  6                Ogbomosho      UTI                             *S. sciuri*                              PEN, OXA, GEN, CIP, FUS                    \+                 NT

KEY:^ψ^: Representative MRCNS for SCC*mec* typing determined by Kondo *et al*. (2007); *UTI:* Urinary Tract Infection; *SSI:* Skin and soft tissue infection; *GTI:* Genital Tract Infection. Antibiotics - *PEN:* Penicillin; *OXA:* Oxacillin; *GEN:* Gentamicin; CIP: Ciprofloxacin; MOX: Moxifloxacin; ERY: Erythromycin*; CLI:* Clindamycin; *TET:* Tetracycline; *FUS:* Fusidic acid; *RIF:* Rifampicin; *COT:* Cotrimoxazole; *TEICO:* Teicoplanin. \*: Inducible resistance (clindamycin); *ND:* Not determined; *NT:* Non-typeable; *UNT:* Untypeable SCC*mec* types.

Antibiotic susceptibility of the staphylococcal isolates and detection of *mecA* and *dfrA* genes
-------------------------------------------------------------------------------------------------

All the staphylococcal isolates were susceptible to mupirocin, tigecycline, vancomycin and linezolid (Table [4](#T4){ref-type="table"}). In addition to the antibiotics stated above, the methicillin-susceptible *S. aureus* (MSSA) were susceptible to teicoplanin, gentamicin, erythromycin, clindamycin, fusidic acid and rifampicin. About 94% of MSSA were susceptible to the fluoroquinolones and one isolate was susceptible to all the antibiotics tested. However, 80.6% of MSSA were resistant to cotrimoxazole and penicillin, but all the cotrimoxazole-resistant MSSA were *dfrA* negative. The predominant antibiotype was resistance to penicillin, tetracycline and cotrimoxazole, which was observed in 14 isolates (39%). Resistance to oxacillin was detected in 15 *S. aureus* isolates and confirmed as MRSA by the detection of the *mecA* gene. Of the 15 MRSA isolates, 13 were resistant to cotrimoxazole and tetracycline, while 6 and 7 MRSA were resistant to gentamicin and ciprofloxacin, respectively. Two of the 5 erythromycin-resistant MRSA expressed inducible resistance to clindamycin. Overall, 12 of the 15 MRSA were resistant to at least three classes of antibiotics (Table [1](#T1){ref-type="table"}). The trimethoprim resistance gene, *dfrA*, was detected in only 3 MRSA isolates.

###### 

Antibiotic resistance profile of staphylococci from Nigeria

                    **Number (%) of isolates resistant among**                                       
  ----------------- -------------------------------------------- ----------- ----------------------- ------------------
  **Antibiotics**   **MSSA**                                     **MRSA**    ***S. haemolyticus***   **Others (CNS)**
  **n=36**          **n=15**                                     **n=21**    **n=19**                
  Penicillin        29 (80.6)                                    15 (100)    21 (100)                18 (94.7)
  Oxacillin         0 (0)                                        15 (100)    21 (100)                12 (63.2)
  Teicoplanin       0 (0)                                        0 (0)       1\* (4.8)               0 (0)
  Vancomycin        0 (0)                                        0 (00       0 (0)                   0 (0)
  Gentamicin        0 (0)                                        6 (40)      18 (85.7)               9 (47.4)
  Tetracycline      21 (58.3)                                    13 (86.7)   19 (90.5)               9 (47.4)
  Ciprofloxacin     2 (5.6)                                      7 (46.7)    17 (80.9)               9 (47.4)
  Moxifloxacin      1 (2.8)                                      1 (6.7)     6 (28.6)                3 (15.8)
  Erythromycin      0 (0)                                        5 (33.3)    10 (47.6)               0 (0)
  Clindamycin       0 (0)                                        5 (33.3)    5 (23.8)                0 (0)
  Fusidic acid      0 (0)                                        1 (6.7)     1 (4.8)                 16 (84.2)
  Tigecycline       0 (0)                                        0 (0)       0 (0)                   0 (0)
  Mupirocin         0 (0)                                        0 (0)       0 (0)                   0 (0)
  Linezolid         0 (0)                                        0 (0)       0 (0)                   0 (0)
  Rifampicin        0 (0)                                        2 (13.3)    4 (19)                  0 (0)
  Cotrimoxazole     29 (80.6)                                    13 (86.7)   21 (100)                8 (42.1)

\*Intermediate resistance.

All the *S. haemolyticus* isolates were resistant to penicillin, oxacillin and cotrimoxazole, but only one isolate exhibited resistance to fusidic acid. The proportion of *S. haemolyticus* isolates resistant to ciprofloxacin, gentamicin and tetracycline was 80.9%, 85.7% and 90.5%, respectively (Table [4](#T4){ref-type="table"}). Furthermore, 5 (50%) of the 10 erythromycin-resistant *S. haemolyticus* isolates expressed inducible resistance to clindamycin, and one isolate showed intermediate resistance to teicoplanin (MIC: 16μg/ml). Multiresistant *S. haemolyticus* isolates were recovered from clinical samples in four HCIs in Lagos2, Maiduguri, Jos and Ogbomosho (Table [3](#T3){ref-type="table"}). In contrast, resistance to fusidic acid was common in other species of CNS, and they were susceptible to erythromycin, clindamycin, teicoplanin and rifampicin (Table [4](#T4){ref-type="table"}). The *S. sciuri* isolates were resistant to oxacillin and obtained primarily from various clinical samples in Ogbomosho (Table [3](#T3){ref-type="table"}). On the whole, multiresistance was observed in 37 of the 40 CNS isolates, and the CNS isolates identified as methicillin-resistant (VITEK) were *mecA* positive.

SCC*mec* typing
---------------

Fifteen MRSA were obtained from the HCIs in Ile-Ife (n=5); Maiduguri (n=4); Lagos1 (n=3); Ibadan (n=2) and Iwo (n=1). Using the multiplex typing method \[[@B26]\], SCC*mec* type IV was identified in two MRSA each from Ile-Ife and Maiduguri, SCC*mec* type III in two MRSA, one each from Ile-Ife and Lagos1, and SCC*mec* type II in one MRSA from Ile-Ife (Table [1](#T1){ref-type="table"}). However, 8 of 15 MRSA and 28 methicillin-resistant CNS (MRCNS) were non-typeable. Based on another PCR-based method \[[@B27]\], two of the four representative MRSA and three *S. haemolyticus* possessed the SCC*mec* V element (*ccrC*/Class C2 *mec*). However, untypeable SCC*mec* elements were detected in two MRSA (*ccrC*/Class A *mec* and *ccr*-negative/Class C2 *mec*) and one isolate each of *S. sciuri* and *S. haemolyticus* (*ccr*-negative/Class A *mec* and *ccr* type 4/Class C2 *mec* gene complex) (Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}).

Detection of PVL gene
---------------------

One MRSA from Ile-Ife was PVL positive (Table [1](#T1){ref-type="table"}). The gene was also detected in 16 MSSA, of which 10 were isolated from patients with SSI and septicaemia (Table [2](#T2){ref-type="table"}).

Molecular typing of MSSA and MRSA
---------------------------------

A total of 21 *spa* types were identified and representative *S. aureus* strains assigned as t037, t064, t084, t355, t2331, t4690, and new types t8987 and t9008 were selected for MLST (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). In MRSA, seven different *spa* types were identified and isolates with *spa* types t037, t064, and t4690 were assigned ST241, ST8 and ST152, respectively. Overall, the clonal complexes for MRSA were distributed across CC8, CC30, CC88 and ST152 (Table [2](#T2){ref-type="table"}). In MSSA, fifteen different *spa* types, including two new types (t8987 and t9008) were identified of which only t064 was identified also in MRSA (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The predominant *spa* types were t355 (8 isolates), t084 (7 isolates) and t318 (3 isolates) and a diversity of *spa* types (t318, t1510, t2304, t2331, *spa* non-typeable) were identified among the MSSA from nasal samples of health care workers (HCWs) (Table [2](#T2){ref-type="table"}). MSSA isolates with *spa* type t084 and t2331 were assigned ST15 and ST8 respectively, while ST152 accounted for the new *spa* types (t8987, t9008) and t355. Nine and 11 of the 36 MSSA clustered with ST15 and ST152 respectively (Table [2](#T2){ref-type="table"}).

Discussion
==========

The identification of bacterial isolates to species level is of great importance in the clinical microbiology laboratory to obtain information on the diversity and significance of each species in human infection. Moreover, species identification is a prerequisite for epidemiological studies. Many clinical microbiology laboratories in Nigeria do not identify staphylococci (in particular CNS) to species level, which is important in understanding their variety and clinical relevance. Two species, *S. haemolyticus* and *S. sciuri*, accounted for the majority of the 40 CNS isolates investigated in this study (Table [3](#T3){ref-type="table"}). Most of the *S. haemolyticus* isolates were obtained from blood culture samples in HCIs in Lagos2 and Jos, and *S. sciuri* from samples in Ogbomosho (South-West Nigeria). *S. haemolyticus* is regarded as the second most frequently isolated staphylococci from blood cultures \[[@B32]\] and one of the most clinically relevant CNS, particularly in immunocompromised patients \[[@B33]\]. *S. sciuri*, principally found in animal species, and although not considered important from the clinical standpoint, has been associated with infections such as endocarditis \[[@B34]\], urinary tract infection \[[@B35]\] and wound infections \[[@B19],[@B36]\]. Multiresistance to antibiotics was detected in 37 of the 40 CNS isolates, and all the *S. haemolyticus* isolates were resistant to at least three classes of antibiotics. Apart from the possible clinical importance because of its serious impact on the course of infection, multiresistant CNS are a potential source of genes encoding resistance to antibiotics for other staphylococci pathogenic for man. The isolation of multiresistant *mecA* positive *S. haemolyticus* from blood samples (septicaemia) and *S. sciuri* from various clinical materials (Table [3](#T3){ref-type="table"}) in some HCIs clearly indicate that they could be of clinical importance in Nigeria. A number of reports have indicated an increase in the resistance of staphylococci to cotrimoxazole in Nigeria \[[@B15],[@B18],[@B21],[@B23],[@B37]\]. In this study, 72.5% of CNS and 82.3% of *S. aureus* isolates were resistant to cotrimoxazole. The antibiotic has wide clinical application, inexpensive, orally administered and available over-the-counter where they are sold with or without prescription in Nigeria. This could possibly explain the high level of staphylococcal resistance observed in this study. Most of the cotrimoxazole-resistant *S. aureus* were *dfrA*-negative; hence more studies are needed to understand the molecular mechanism of resistance in Nigeria.

Methicillin resistance in staphylococci is due to the expression of the *mecA* gene, which mediates penicillin binding protein 2a (PBP2a), a transpeptidase with low affinity for beta-lactams \[[@B7],[@B38]\]. The *mecA* gene is carried by a mobile genetic element (MGE) termed the staphylococcal cassette chromosome (SCC*mec*), and though the *mec* origin remains unknown, it has been suggested that *mecA* CNS may act as potential SCC*mec* donor accounting for the rise of new MRSA clones \[[@B39]\]. Eleven SCC*mec* elements have been described to date: SCC*mec* I-IV \[[@B40]-[@B42]\], and V-XI \[[@B43]-[@B48]\], but few reports exist on the detection of *mecA* gene and characterization of SCC*mec* types in Nigeria \[[@B21]-[@B23]\]. There was excellent correlation between results of antibiotic susceptibility testing (VITEK) and detection of the *mecA* gene for the confirmation of methicillin-resistant staphylococci. However, the MRCNS were non-typeable using the multiplex PCR protocol \[[@B26]\]. Based on the method of Kondo et al. \[[@B27]\], the SCC*mec* V element (*ccrC*/Class C2 *mec*) was identified in representative *S. haemolyticus* isolates, as well as untypeable SCC*mec* elements (*ccr*-negative/Class A *mec* and *ccr* type 4/Class C2 *mec* gene complex) in one representative isolate each of *S. sciuri* and *S. haemolyticus* (Table [3](#T3){ref-type="table"}). Recent studies have indicated that SCC*mec* V is the predominant element among methicillin-resistant *S. haemolyticus* isolates \[[@B33],[@B49]\]. To the best of our knowledge, this is the first report on the characterization of SCC*mec* elements in CNS in Nigeria. It is likely that the *mec* gene complex and *ccr* genes in CNS are diverse and distinct, and as indicated in previous reports \[[@B7],[@B28]\], there is the need to develop new classification schemes for non-typeable SCC*mec* types in MRCNS.

Molecular typing of the MRSA isolates indicated that two clones (CC8-SCC*mec*non-typeable and CC88-SCC*mec* IV) existed in Maiduguri, North-East Nigeria, and four clones in South-West Nigeria (CC8-SCC*mec*III/IV/V; CC30-SCC*mec*II/III; CC88-SCC*mec*IV and ST152-SCC*mec*non-typeable) (Table [1](#T1){ref-type="table"}). Previous studies on the epidemiology of MRSA in Nigeria identified MRSA clones t064-ST8-CC8 and t037-ST241-CC8 in South-West and North-East Nigeria, respectively \[[@B22],[@B23]\]. A community-associated clone, CC88-MRSA-IV, previously reported in Ibadan, Nigeria \[[@B21]\] was identified from wound and blood samples in Maiduguri and Ile-Ife, however, we were unable to determine whether the isolates were community-associated. Untypeable SCC*mec* types (*ccrC*/Class A *mec*; *ccr*-negative/Class C2 *mec*) were detected in two representative MRSA isolates, of which one was a PVL-positive isolate (t4690-ST152) from a patient with osteomyelitis in Ile-Ife (South-West Nigeria).

The MSSA were assigned mainly to clonal complexes CC5, CC8, CC15, CC30, CC45, CC80 and ST152 (Table [2](#T2){ref-type="table"}). A high proportion of MSSA from Maiduguri were grouped in ST15 or ST152 indicating that these clones were successful in North East Nigeria. PVL-encoding genes were detected in 16 MSSA (44.4%) isolates belonging to almost all clonal complexes identified in this study. Moreover, 56% of these strains were associated with ST152 and 10 of 16 (62.5%) PVL positive MSSA isolates were associated with SSI and septicaemia. These observations confirm previous studies that PVL-positive MSSA ST152 are widespread in African countries \[[@B50]-[@B52]\] including Nigeria \[[@B22],[@B23]\]. Furthermore, MSSA isolates (ST121) from nasal samples of HCWs were PVL positive. Our data suggests that the sequence types for pandemic PVL-positive MSSA identified in this study did not function as a reservoir for PVL-positive MRSA supporting the argument of Schaumburg et al. \[[@B52]\] that the intimate inter-relation between PVL-positive MSSA and MRSA, which could lead to the emergence and spread of PVL-positive MRSA clones has not been established. However, the detection of an ST152-PVL-positive MRSA in this study suggests that surveillance for this clone is strongly advocated in Nigeria.

Conclusions
===========

This is the first multi-centre study on the characterization of coagulase positive and negative staphylococci using phenotypic and molecular methods in Nigeria. However, there were a number of limitations in this study. The number of isolates from the HCIs was low and variable which did not allow for comparison of data among the participating centres. Moreover, the diversity of the staphylococci analysed in this study does not represent their distribution patterns in health care institutions in Nigeria. Lastly, we could not conduct full characterization of the *mecA*-positive CNS isolates, and only representative isolates were selected for SCC*mec* typing and MLST. However, this study has highlighted the importance of species identification for CNS, their clinical relevance, and the need for longitudinal multi-centre surveys to provide data on antibiotic resistance and epidemiology of the staphylococci in Nigeria. Characterization of multiresistant *mecA* positive *S. haemolyticus* and *S. sciuri* from clinical samples is important in understanding their epidemiology within hospitals in Nigeria. The identification of untypeable SCC*mec* types in the study will be further evaluated and characterized; however, there is the need to develop new SCC*mec* classification schemes for non-typeable methicillin-resistant staphylococci. There is an urgent need to curtail the spread and establishment of PVL-positive MSSA, in particular, the MSSA ST152 clone, in Nigeria.
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